Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
P. Angulo, K.D. Lindor.
Primary sclerosing cholangitis.
Hepatology, 30 (1999), pp. 325-332
[2.]
E. Schrumpf, K.M. Boberg.
Epidemiology of primary sclerosing cholangitis.
Best Prac Clin Res Gastroenterol, 15 (2001), pp. 553-562
[3.]
A. Escorsell, A. Pares, J. Rodes, J.A. Solis-Herruzo, M. Miras, E. De la Morena.
Epidemiology of primary sclerosing cholangitis in Spain.
J Hepatol, 21 (1994), pp. 787-791
[4.]
K.M. Boberg, C. Aadland, J. Jahnsen, N. Raknerud, M. Stiris, H. Bell.
Incidence and prevalence of primary biliary cirrosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population.
Scand J Gastroenterol, 33 (1998), pp. 99-103
[5.]
K. Bambha, W.R. Kim, J. Talwalkar, H. Torgerson, J.T. Benson, T.M. Therneau, et al.
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.
Gastroenterology, 126 (2003), pp. 1364-1369
[6.]
Y.M. Lee, M.M. Kaplan.
Primary sclerosing cholangitis.
N Engl J Med, 332 (1995), pp. 924-933
[7.]
O. Fausa, E. Schrumpf, K. Elgjo.
Relationship of inflammatory bowel disease and primary sclerosing cholangitis.
Sem Liv Dis, 11 (1991), pp. 31-39
[8.]
A.L. Mason, L. Xu, L. Guo, R.F. Garry.
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders.
Lancet, 351 (1998), pp. 1620-1624
[9.]
B.N. Brooke, P.W. Dykes, F.C. Walker.
A study of liver disorder in ulcerative colitis.
Postgrad Med J, 37 (1961), pp. 245-251
[10.]
R. Olsson, E. Bjornsson, L. Backman, S. Friman, K. Hockerstetd, B. Kaijser, et al.
Bile duct bacterial isolates in PSC: a study of explanted livers.
J Hepatol, 28 (1998), pp. 426-432
[11.]
J. Vierling.
Aetiopathogenesis of primary sclerosing cholangitis.
Primary sclerosing cholangitis, pp. p37-p45
[12.]
S.A. Mitchell, M. Thyssen, T.R. Orchard, D.P. Jewell, K.A. Fleming, R.W. Chapman.
Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.
Gut, 51 (2002), pp. 567-573
[13.]
R.W. Chapman, Z. Varghese, R. Gaul, G. Patel, N. Kininon, S. Sherlock.
Association of primary sclerosing cholangitis with HLA-B8.
Gut, 24 (1983), pp. 38-41
[14.]
E.J. Prochazka, P.I. Terasaki, M.S. Park, L.I. Goldstein, R.W. Busuttil.
Association of primary sclerosing cholangitis with HLADRw52a.
N Engl J Med, 322 (1990), pp. 1842-1844
[15.]
H. Zetterquist, U. Broome, K. Einarsson, O. Olerup.
HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in swedish patients with sclerosing cholangitis.
Gut, 33 (1992), pp. 942-946
[16.]
A. Spurkland, S. Saarinen, K.M. Boberg, S. Mitchell, U. Broome, L. Caballeria, et al.
HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations.
Tissue Antigens, 53 (1999), pp. 459-469
[17.]
S.A. Mitchell, J. Grove, A. Spurkland, K.M. Boberg, K.A. Fleming, C.P. Day, et al.
Association of the TNFα-308 but not the interleukin-10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis.
Gut, 49 (2001), pp. 288-294
[18.]
J. Satsangi, R.W. Chapman, N. Haldar, et al.
A functional polymorphism of the stromelysin gene (MMP-3) incfluences susceptibility to primary sclerosing cholangitis.
Gastroenterology, 121 (2001), pp. 124-130
[19.]
J.M. Farrant, K.M. Hayllar, M.L. Wilkinson, J. Karani, B. Portmann, D. Westaby, et al.
Natural history and prognostic variables in primary sclerosing cholangitis.
Gastroenterology, 100 (1991), pp. 1710-1717
[20.]
R.H. Wiesner, P.M. Grambsch, E.R. Dickson, J. Ludwig, R.L. MacCarty, E.B. Hunter, et al.
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.
Hepatology, 10 (1989), pp. 430-436
[21.]
M.K. Porayto, R.H. Wiesner, N.F. LaRusso, J. Ludwig, R.L. MacCarty, B.L. Steiner, et al.
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease.
Gastroenterology, 98 (1990), pp. 1594-1602
[22.]
U. Broome, R. Olsson, L. Loof, R. Hultcrantz, A. Danielsson, G. Bodemar, et al.
Natural history and prognostic factors in 305 swedish patients with primary sclerosing cholangitis.
Gut, 38 (1996), pp. 610-1615
[23.]
K.M. Boberg, G. Rocca, T. Egeland, A. Bergquist, U. Broome, L. Caballeria, et al.
Time-dependent cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis.
Hepatology, 35 (2002), pp. 6512-6657
[24.]
B. Terjung, U. Spoengler, T. Sauerbruch, H.J. Worman.
Atypical p-ANCA in IBD and hepatobiloary dosorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.
Gastroenterology, 119 (2000), pp. 310-322
[25.]
P. Angulo, Y. Maor-Kendler, K.D. Lindor.
Small-duct sclerosing cholangitis: a long-term follow-up.
Hepatology, 35 (2002), pp. 1494-1500
[26.]
U. Broome, H. Glaumann, E. Lindstom, L. Loof, S. Almer, H. Prytz, et al.
Natural history and outcome in 32 swedish patiens with small duct primary sclerosing cholangitis (SPC).
J Hepatol, 36 (2002), pp. 586-589
[27.]
E. Bjornsson, K.M. Boberg, S. Cullen, K. Fleming, O.P. Clausen, O. Fausa, et al.
Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis.
Gut, 51 (2002), pp. 731-735
[28.]
R.W. Chapman.
Small duct primary sclerosing cholangitis.
J Hepatol, 36 (2002), pp. 692-694
[29.]
G. Mieli-Vergani, D. Vergani.
Sclerosing cholangitis in the paediatric patient.
Best Pract Res Clin Gastroenterol, 15 (2001), pp. 681-690
[30.]
M. Wilschanski, P. Chait, J.A. Wade, L. Davis, M. Corey, P. StLouis, et al.
Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis.
Hepatology, 22 (1995), pp. 1415-1422
[31.]
O. Ernst, T. Asselah, N. Talbodec, G. Sergent.
MR cholangiopancreatography: a promising new tool for diagnosing primary sclerosing cholangitis.
AJR Am J Roentgenol, 168 (1997), pp. 1115-1116
[32.]
K. Ito, D.G. Mitchell, E.K. Outwater, R. Blasbalg.
Primary sclerosing cholangitis: MR imaging features.
AJR Am J Roentgenol, 172 (1999), pp. 1527-1533
[33.]
G.P. Jeffrey, W.D. Reed, D. Carrello, K.B. Shilkin.
Histological and immunohistochemical study of the gallbladder lesion in primary sclerosing cholangitis.
Gut, 32 (1991), pp. 424-429
[34.]
K.M. Vitellas, A. El-Dieb, K.K. Vaswani, W.F. Bennett, M. Tzalonikou, C. Mabee, et al.
MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography.
AJR Am J Roentgenol, 179 (2002), pp. 399-407
[35.]
J. Ludwig, S.S. Barham, N.F. LaRusso, L.R. Elbeback, R.H. Wiesner, J.T. MCCall.
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.
Hepatology, 1 (1981), pp. 632-640
[36.]
K.W. Burak, P. Angulo, K.D. Lindor.
Is there a role for liver biopsy in primary sclerosing cholangitis?.
Am J Gastroenterol, 98 (2003), pp. 1155-1158
[37.]
A.A. Abdo, V.G. Bain, K. Kichian, S.S. Lee.
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome.
Hepatology, 36 (2002), pp. 1393-1399
[38.]
K. Shetty, L. Rybicki, W.D. Carey.
The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis.
Hepatology, 25 (1997), pp. 1049-1053
[39.]
C.Y. Ponsioen, S.M. Vrouenraets, W. Prawirodirdjo, R. Rajaram, E.A. Rauws, C.J. Mulder, et al.
Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a dutch population.
Gut, 51 (2002), pp. 562-566
[40.]
A.E. Feldstein, J. Perrault, M. El Youssif, K.D. Lindor, D.K. Freese, P. Angulo.
Primary sclerosing cholangitis in children: a longterm follow-up study.
Hepatology, 38 (2003), pp. 210-217
[41.]
A. Bergquist, A. Ekbom, R. Olsson, D. Kornfeldt, L. Loof, A. Danielsson, et al.
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
J Hepatol, 36 (2002), pp. 321-327
[42.]
K.M. Boberg, A. Bergquist, S. Mitchell, A. Parés, F. Rosina, U. Broome, et al.
Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.
Scand J Gastroenterol, 37 (2002), pp. 1205-1211
[43.]
D.C. Buckles, K.D. Lindor, N.F. Larusso, L.M. Petrovic, G.J. Gores.
Primary sclerosing cholangitis, gallbladder polyps are frequently malignant.
Am J Gastroenterol, 97 (2002), pp. 1138-1142
[44.]
R.M. Soetikno, O.S. Lin, P.A. Heidenreich, H.S. Young, M.O. Blackstone.
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.
Gastrointest Endosc, 56 (2002), pp. 48-54
[45.]
W.L. Campbell, J.V. Ferris, B.L. Holbert, F.L. Thaete, R.L. Baron.
Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT, cholangiography, US, and MR imaging.
Radiology, 207 (1998), pp. 41-50
[46.]
S. Keiding, S. Hansen, H. Rasmussen, A. Gee, A. Kruse, K. Roelsgaard, et al.
Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.
Hepatology, 28 (1998), pp. 700-706
[47.]
J. Ramage, A. Donaghy, J. Farrant, R. Iorns, R. Williams.
Serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.
Gastroenterology, 108 (1995), pp. 865-869
[48.]
R. Hultcrantz, R. Olsson, A. Danielsson, G. Jarnerot, L. Loof, B.O. Ryden, et al.
A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
J Hepatol, 30 (1999), pp. 669-673
[49.]
M. Rabinovitz, A. Zajko, T. Hassanein, B. Shetty, K.M. Bron, R.R. Schade, et al.
Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures.
Hepatology, 12 (1990), pp. 747-752
[50.]
K. Boberg, E. Schrumpf, A. Bergquist, U. Broome, A. Pares, H. Remotti, et al.
Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
J Hepatol, 32 (2000), pp. 374-380
[51.]
Y.M. Lee, M.M. Kaplan.
Management of primary sclerosing cholangitis.
Am J Gastroenterol, 97 (2002), pp. 528-534
[52.]
N. Guañabens, A. Parés, I. Ros, L. Álvarez, F. Pons, L. Caballería, et al.
Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
Am J Gastroenterol, 98 (2003), pp. 2268-2274
[53.]
A. Parés, L. Cisneros, J.M. Salmerón, A. Caballería, A. Mas, A. Torras, et al.
Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrosis.
J Hepatol, 36 (2002), pp. 155
[54.]
K.D. Lindor.
Ursodiol for primary sclerosing cholangitis.
N Engl J Med, 336 (1997), pp. 691-695
[55.]
S.A. Mitchell, D. Bansi, N. Hunt, J. Christie, K. Fleming, R. Chapman.
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Gastroenterology, 121 (2001), pp. 900-907
[56.]
D.M. Harnois, P. Angulo, R.A. Jorgensen, N. LaRusso, K.D. Lindor.
High dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Am J Gastroenterol, 96 (2001), pp. 1164-1169
[57.]
D.S. Pardi, E.V. Loftus Jr, W.K. Kremers, J. Keach, K.D. Lindor.
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Gastroenterology, 124 (2003), pp. 889-893
[58.]
M. Farkkila, P. Karkkainen, A. Karvonen, H. Nuutinen, H. Nurmi, P. Pikkarainen.
Combination of ursodeoxycholic acid (UDCA) and metronidazole (MTZ) in PSC: reduction of inflammation in liver correlates with the decrease in the new Mayo Risk Score.
Gastroenterology, 124 (2003), pp. A707
[59.]
A. Wagner.
Azathioprine treatment in primary sclerosing cholangitis.
Lancet, 2 (1971), pp. 663-664
[60.]
R. Olsson, U. Broome, A. Danielsson, I. Hagerstrand, G. Jarnerot, L. Loof, et al.
Colchicine treatment of primary sclerosing cholangitis.
Gastroenterology, 108 (1995), pp. 1199-1203
[61.]
K.D. Lindor, R.H. Wiesner, L.J. Colwell, B. Steiner, S. Beaver, N.F. La-Russo.
The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.
Am J Gastroenterol, 86 (1991), pp. 57-61
[62.]
N.F. LaRusso, R.H. Wiesner, J. Ludwig, R.L. MacCarty, S.J. Beaver, A.R. Zinsmeister.
Prospective trial of penicillamine in primary sclerosing cholangitis.
Gastroenterology, 95 (1988), pp. 1036-1042
[63.]
R. Wiesner, B. Steiner, N. LaRusso.
A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis.
Hepatology, 14 (1991), pp. A63
[64.]
D.H. Van Thiel, P. Carroll, K. Abu-Elmagd, H. Rodríguez-Rilo, W. Irish, J. McMichael, et al.
Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.
Am J Gastroenterol, 90 (1995), pp. 455-459
[65.]
T.A. Knox, M.M. Kaplan.
Treatment of primary sclerosing cholangitis with oral methotrexate.
Am J Gastroenterol, 86 (1991), pp. 546-552
[66.]
T.A. Knox, M.M. Kaplan.
A double-blind controlled trial of oralpulse methotrexate therapy in the treatment of primary sclerosing cholangitis.
Gastroenterology, 106 (1994), pp. 494-499
[67.]
A.E. Bharucha, R. Jorgensen, S.N. Lichtman, N.F. LaRusso, K.D. Lindor.
A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.
Am J Gastroenterol, 95 (2000), pp. 2338-2342
[68.]
P. Angulo, A.E. Bharucha, R.A. Jorgensen, C.K. DeSotel, W.J. Sandborn, N.F. Larusso, et al.
Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.
Dig Dis Sci, 44 (1999), pp. 602-607
[69.]
A. Stiehl, G. Rudolph, P. Kloters-Plachky, P. Sauer, S. Walker.
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.
J Hepatol, 36 (2002), pp. 151-156
[70.]
A. Stielh, G. Rudolph, P. Sauer, et al.
Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.
J Hepatol, 26 (1997), pp. 560-566
[71.]
F. Berr, M. Wiedmann, A. Tannapfel, U. Halm, K.R. Kohlhaw, F. Schmidt, et al.
Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.
Hepatology, 31 (2000), pp. 291-298
[72.]
J. Harrison, P. McMaster.
The role of orthotopic liver transplantation in the management of sclerosing cholangitis.
Hepatology, 20 (1994), pp. 14-19
[73.]
U. Broome, L.S. Eriksson.
Assessment for liver transplantation in patients with primary sclerosing cholangitis.
J Hepatol, 20 (1994), pp. 654-659
[74.]
I.W. Graziadei, R.H. Wiesner, P.J. Marotta, M.K. Porayko, J.E. Hay, M.R. Charlton, et al.
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis.
Hepatology, 30 (1999), pp. 1121-1127
[75.]
I.W. Graziadei.
Recurrence of primary sclerosing cholangitis after liver transplantation.
Liver Transpl, 8 (2002), pp. 575-581
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
